The mechanism by which a HFD promotes CRC was verified by oral administration of Cori.ST1911 combined with intraperitoneal injection of the CPT1-specific inhibitor etomoxir into BALB/c mice with subcutaneously transplanted tumours (Fig. 5H). The gene discussed is CPT2; the disease is colorectal carcinoma.